Prothena Corp Public Ltd Co (PRTA) Stock Analysis and Metrics

Prothena Corp Public

NASDAQ: PRTA

$8.77 ▲ +0.24 (+2.75%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap467.80 Mn

P/E-3.10

P/S8.07

Div. Yield0.00

Revenue Growth (1y) (Qtr)1,706.36

Add ratio to table…

About

Prothena Corporation plc is a late stage clinical biotechnology company that concentrates on protein dysregulation to create treatments for neurodegenerative and rare peripheral amyloid diseases. The firm leverages its proprietary CYTOPE® platform to target intracellular disease pathways in the brain and periphery. Its pipeline includes wholly owned and partnered programs aimed at conditions such as Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, amyotrophic lateral sclerosis and other neurodegenerative disorders. The company’s strategy is to advance its clinical candidates through partnerships while investing in early stage research to generate future collaboration opportunities.

Revenue is generated mainly from upfront payments, milestone payments and royalties received under licensing and collaboration agreements with pharmaceutical partners. For example, the agreement with Roche included an upfront payment of $30 million and milestone payments of $30 million and $60 million for the initiation of Phase 2 and Phase 2b studies. The collaboration with Novo Nordisk involved an upfront payment and potential milestones worth up to $1.23 billion, of which approximately $100 million has been earned to date. Agreements with Bristol Myers Squibb provided upfront option exercise fees of $80 million, $55 million and $80 million for the programs targeting tau, neurodegenerative disease and a separate antibody, respectively, plus eligibility for additional milestones and royalties. These arrangements allow the company to recognize revenue as development progresses and as sales milestones are achieved.

Prothena operates in a highly competitive biotechnology environment where larger pharmaceutical and biotech firms possess greater financial resources, larger research staff and established commercial infrastructures. Despite this, the company maintains a differentiated position through its deep expertise in the biology of misfolded proteins and its proprietary CYTOPE® technology that enables targeting of intracellular pathways previously considered undruggable. The firm’s pipeline of partnered clinical stage programs, including those for Parkinson’s disease, ATTR amyloidosis and Alzheimer’s disease, provides validation of its scientific approach and reduces reliance on internal financing for later stage development. These factors give Prothena a competitive edge in attracting collaborations and in advancing its candidates toward potential regulatory approval.

The company’s customers are the pharmaceutical firms that collaborate on its drug development programs. These partners include Roche, which is developing the alpha synuclein antibody prasinezumab for Parkinson’s disease; Novo Nordisk, which is advancing the anti TTR antibody coramitug for ATTR cardiomyopathy; and Bristol Myers Squibb, which is conducting programs for tau targeted and neurodegenerative disease therapeutics. Through these relationships, the company receives funding, shares development costs and is positioned to earn royalties on any future product sales.

Investment Thesis

▲ Bull case

Prothena is significantly underestimating the near-term value creation potential from its partnership with Novo Nordisk on coramitug, particularly given the recent $50 million milestone payment tied to Phase 3 CLEOPATTRA enrollment and the FDA’s Fast Track Designation, which together signal strong partner commitment and de-risking of the ATTR-CM program. The market appears to overlook that Novo Nordisk’s $1.2 billion total potential consideration—of which $150 million has already been earned—includes near-term clinical and regulatory milestones that could trigger additional payments well before the 2029 primary completion date, especially as Fast Track Designation often accelerates interactions with the FDA and increases the likelihood of priority review or accelerated approval pathways. This is further reinforced by Prothena’s updated 2026 guidance, which now excludes only $55 million in potential PRX019 milestones from BMS but still implies upside from Novo Nordisk collaboration beyond what is modeled, suggesting the Street may be underappreciating the optionality embedded in the ATTR-CM franchise. With no debt and over $330 million in cash as of Q1 2026, Prothena has ample financial flexibility to weather near-term volatility while these partnered programs mature, reducing the risk of dilutive financing and preserving upside for shareholders.
The company’s preclinical pipeline, particularly the CYTOPE® technology platform and its application in TDP-43-targeted therapies for ALS and other proteinopathies, represents a hidden catalyst that management has not heavily promoted in recent communications but could unlock substantial long-term value. While the Q1 2026 results highlighted ongoing research collaborations exploring CYTOPE®, the lack of detailed financial or clinical timelines around this technology may be causing investors to overlook its potential to transform intracellular drug delivery—a critical limitation in treating neurodegenerative diseases like ALS, where most therapeutics fail to cross cellular membranes effectively. The fact that Prothena is actively engaging industry partners on CYTOPE® applications, combined with its wholly-owned status (unlike partnered late-stage assets), means any success here would accrue fully to Prothena, potentially generating licensing revenue, milestone payments, or even co-development deals with major pharma players seeking novel delivery mechanisms. This structural shift toward intracellular targeting addresses a fundamental bottleneck in neuroscience drug development and could position Prothena not just as a provider of antibodies but as a platform technology company—a re-rating opportunity the market is currently ignoring.
Prothena’s share repurchase authorization of up to $100 million, coupled with its updated 2026 cash guidance showing an increased year-end balance of ~$273 million (up from prior $255 million midpoint), signals strong confidence from the Board and management in the company’s intrinsic value, especially given that this return of capital is being funded in part by non-dilutive milestone payments. The repurchase of 788,990 shares for $7.3 million in Q1 2026 alone demonstrates active execution, and with the program running through December 2026, there remains significant capacity to buy back shares at what may be distressed levels relative to future pipeline value. This is particularly meaningful because the buyback is occurring despite ongoing R&D investment in preclinical programs like CYTOPE® and PRX012-TfR, indicating that leadership believes the core business is generating sufficient cash flow from collaborations to fund both innovation and shareholder returns—a balance that is often mispriced in biotech markets where companies are either seen as pure cash burners or premature returners of capital. The reduction in share count (from ~53.8M to ~52.4M) already enhances earnings per share potential, and continued repurchases could meaningfully boost per-share metrics even if net income remains modest, creating a floor for valuation that the market is not fully incorporating.

Prothena is significantly underestimating the near-term value creation potential from its partnership with Novo Nordisk on coramitug, particularly given the recent $50 million milestone payment tied to Phase 3 CLEOPATTRA enrollment and the FDA’s Fast Track Designation, which together signal strong partner commitment and de-risking of the ATTR-CM program. The market appears to overlook that Novo Nordisk’s $1.2 billion total potential consideration—of which $150 million has already been earned—includes near-term clinical and regulatory milestones that could trigger additional payments well before the 2029 primary completion date, especially as Fast Track Designation often accelerates interactions with the FDA and increases the likelihood of priority review or accelerated approval pathways. This is further reinforced by Prothena’s updated 2026 guidance, which now excludes only $55 million in potential PRX019 milestones from BMS but still implies upside from Novo Nordisk collaboration beyond what is modeled, suggesting the Street may be underappreciating the optionality embedded in the ATTR-CM franchise. With no debt and over $330 million in cash as of Q1 2026, Prothena has ample financial flexibility to weather near-term volatility while these partnered programs mature, reducing the risk of dilutive financing and preserving upside for shareholders.
The company’s preclinical pipeline, particularly the CYTOPE® technology platform and its application in TDP-43-targeted therapies for ALS and other proteinopathies, represents a hidden catalyst that management has not heavily promoted in recent communications but could unlock substantial long-term value. While the Q1 2026 results highlighted ongoing research collaborations exploring CYTOPE®, the lack of detailed financial or clinical timelines around this technology may be causing investors to overlook its potential to transform intracellular drug delivery—a critical limitation in treating neurodegenerative diseases like ALS, where most therapeutics fail to cross cellular membranes effectively. The fact that Prothena is actively engaging industry partners on CYTOPE® applications, combined with its wholly-owned status (unlike partnered late-stage assets), means any success here would accrue fully to Prothena, potentially generating licensing revenue, milestone payments, or even co-development deals with major pharma players seeking novel delivery mechanisms. This structural shift toward intracellular targeting addresses a fundamental bottleneck in neuroscience drug development and could position Prothena not just as a provider of antibodies but as a platform technology company—a re-rating opportunity the market is currently ignoring.
Prothena’s share repurchase authorization of up to $100 million, coupled with its updated 2026 cash guidance showing an increased year-end balance of ~$273 million (up from prior $255 million midpoint), signals strong confidence from the Board and management in the company’s intrinsic value, especially given that this return of capital is being funded in part by non-dilutive milestone payments. The repurchase of 788,990 shares for $7.3 million in Q1 2026 alone demonstrates active execution, and with the program running through December 2026, there remains significant capacity to buy back shares at what may be distressed levels relative to future pipeline value. This is particularly meaningful because the buyback is occurring despite ongoing R&D investment in preclinical programs like CYTOPE® and PRX012-TfR, indicating that leadership believes the core business is generating sufficient cash flow from collaborations to fund both innovation and shareholder returns—a balance that is often mispriced in biotech markets where companies are either seen as pure cash burners or premature returners of capital. The reduction in share count (from ~53.8M to ~52.4M) already enhances earnings per share potential, and continued repurchases could meaningfully boost per-share metrics even if net income remains modest, creating a floor for valuation that the market is not fully incorporating.

▼ Bear case

Prothena is facing a fundamental misalignment between its cash burn profile and the timelines of its value-driving catalysts, with the market potentially ignoring the extent to which near-term profitability remains elusive despite milestone-driven revenue spikes. While Q1 2026 showed net income of $32.7 million due to the $50 million Novo Nordisk payment, the underlying business continues to burn cash, with updated 2026 guidance projecting a net loss of $25–$30 million for the full year—indicating that the quarterly profit was largely a one-time event tied to a contractual milestone, not sustainable operational performance. The company’s reliance on lump-sum payments from partners creates a lumpy revenue stream that can mask ongoing operational weaknesses, particularly as collaboration revenue from BMS related to PRX019 remains minimal and preclinical programs like CYTOPE® and TDP-43 are still years away from generating any meaningful income, leaving Prothena vulnerable if partner priorities shift or clinical trials face delays.
The advancement of key partnered programs remains subject to significant clinical and regulatory risks that are not being adequately priced in, especially given the long durations to readouts and the historical failure rates in neurodegeneration and amyloid therapies. Prasinezumab’s Phase 3 PARAISO trial in Parkinson’s disease, while supported by encouraging Phase 2 data showing a ‘time saved’ effect, has not yet demonstrated clear clinical benefit in a pivotal setting, and past failures of alpha-synuclein-targeting therapies (e.g., by Roche and others) suggest high skepticism is warranted; similarly, BMS-986446’s Phase 2 TargetTau-1 trial in Alzheimer’s, though ongoing, targets a highly complex and previously unresponsive pathway (tau aggregation), with no guarantee that MTBR-focused antibodies will succeed where others have failed. Coramitug, despite Fast Track Designation and positive Phase 2 signals, is still in a Phase 3 trial with primary completion not expected until 2029, meaning any near-term milestone payments are decoupled from actual efficacy or approval risk—investors may be overestimating the predictability of success in a disease area where even stabilizing therapies like tafamidis have limited uptake, and amyloid-clearing approaches remain unproven in outcomes that matter to patients and payors.
Prothena’s expense structure, while improved YoY, still reflects a company in transition that may struggle to sustain R&D momentum without further partner investment or cost-cutting, with the Q1 2026 G&A and R&D expenses of $12.7 million and $12.6 million respectively implying an annualized run rate of over $100 million—well above what current collaboration revenue can support without additional milestones or cost reductions. The $30.1 million in restructuring charges from 2025 related to the birtamimab program discontinuation and workforce reduction hints at prior over-investment in programs that failed to deliver, raising concerns about capital allocation discipline; although the workforce reduction has lowered the base, the company is now increasing investment in preclinical areas like CYTOPE® and PRX012-TfR, which, while strategically sound, have no near-term path to revenue and could prolong the period of negative free cash flow if partner-driven milestones do not materialize as expected. Furthermore, the share repurchase program, while signaling confidence, risks diverting capital from essential R&D if not carefully managed, especially given that the updated 2026 guidance already factors in ~$15 million in repurchases through April—suggesting that buybacks are being funded partly by cash that might otherwise be used to advance preclinical programs or extend runway, creating a potential tension between shareholder returns and long-term pipeline value that the market may not be scrutinizing closely enough.

Prothena is facing a fundamental misalignment between its cash burn profile and the timelines of its value-driving catalysts, with the market potentially ignoring the extent to which near-term profitability remains elusive despite milestone-driven revenue spikes. While Q1 2026 showed net income of $32.7 million due to the $50 million Novo Nordisk payment, the underlying business continues to burn cash, with updated 2026 guidance projecting a net loss of $25–$30 million for the full year—indicating that the quarterly profit was largely a one-time event tied to a contractual milestone, not sustainable operational performance. The company’s reliance on lump-sum payments from partners creates a lumpy revenue stream that can mask ongoing operational weaknesses, particularly as collaboration revenue from BMS related to PRX019 remains minimal and preclinical programs like CYTOPE® and TDP-43 are still years away from generating any meaningful income, leaving Prothena vulnerable if partner priorities shift or clinical trials face delays.
The advancement of key partnered programs remains subject to significant clinical and regulatory risks that are not being adequately priced in, especially given the long durations to readouts and the historical failure rates in neurodegeneration and amyloid therapies. Prasinezumab’s Phase 3 PARAISO trial in Parkinson’s disease, while supported by encouraging Phase 2 data showing a ‘time saved’ effect, has not yet demonstrated clear clinical benefit in a pivotal setting, and past failures of alpha-synuclein-targeting therapies (e.g., by Roche and others) suggest high skepticism is warranted; similarly, BMS-986446’s Phase 2 TargetTau-1 trial in Alzheimer’s, though ongoing, targets a highly complex and previously unresponsive pathway (tau aggregation), with no guarantee that MTBR-focused antibodies will succeed where others have failed. Coramitug, despite Fast Track Designation and positive Phase 2 signals, is still in a Phase 3 trial with primary completion not expected until 2029, meaning any near-term milestone payments are decoupled from actual efficacy or approval risk—investors may be overestimating the predictability of success in a disease area where even stabilizing therapies like tafamidis have limited uptake, and amyloid-clearing approaches remain unproven in outcomes that matter to patients and payors.
Prothena’s expense structure, while improved YoY, still reflects a company in transition that may struggle to sustain R&D momentum without further partner investment or cost-cutting, with the Q1 2026 G&A and R&D expenses of $12.7 million and $12.6 million respectively implying an annualized run rate of over $100 million—well above what current collaboration revenue can support without additional milestones or cost reductions. The $30.1 million in restructuring charges from 2025 related to the birtamimab program discontinuation and workforce reduction hints at prior over-investment in programs that failed to deliver, raising concerns about capital allocation discipline; although the workforce reduction has lowered the base, the company is now increasing investment in preclinical areas like CYTOPE® and PRX012-TfR, which, while strategically sound, have no near-term path to revenue and could prolong the period of negative free cash flow if partner-driven milestones do not materialize as expected. Furthermore, the share repurchase program, while signaling confidence, risks diverting capital from essential R&D if not carefully managed, especially given that the updated 2026 guidance already factors in ~$15 million in repurchases through April—suggesting that buybacks are being funded partly by cash that might otherwise be used to advance preclinical programs or extend runway, creating a potential tension between shareholder returns and long-term pipeline value that the market may not be scrutinizing closely enough.

Counterparty Name Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Counterparty Name Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Counterparty Name Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password